BOSTON, Jan. 29, 2018 /PRNewswire/ -- The Eventide Healthcare & Life Sciences Fund (NASDAQ: ETIHX *), which celebratedits five-year anniversary in December, completed the five-year period ending December 31, 2017 in the top 1% of the Morningstar Health category for total return out of 121 funds. The Fund ranked in the top 8% for the three-year
The Eventide Healthcare & Life Sciences Fund aims for outperformance by investing in healthcare and life sciences companies creating compelling value for patients and society. Lead portfolio manager Finny Kuruvilla, MD PhD commented, "Biotechnology is perhaps the most exciting and rewarding area to invest today. Scientific and technological advances have now made it possible to address previously intractable unmet medical needs. We focus on small, early development-stage companies developing novel treatments for some of the most devastating diseases afflicting humankind. We believe this approach offers investors the potential for outperformance and the satisfaction in helping to promote human health and wellness."
Finny Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry. He is assisted by research analyst Agustin Mohedas who holds a PhD in Medical Engineering Medical Physics from the Harvard-MIT Division of Health Sciences and Technology and a bachelor's degree in Biomedical Engineering from Texas A&M University.
Morningstar, Inc. All rights reserved. Morningstar is an independent provider of financial information. Wall Street Journal and Morningstar rankings are not intended to constitute investment advice. Rather, you should use the rankings for informational purposes only. Rankings are only one form of performance measurement.
*Rankings differ for other fund classes, based upon fees and commissions. Other share classes: NASDAQ: ETNHX, NASDAQ: ETAHX, NASDAQ: ETCHX.
There is no guarantee that the Adviser will meet its objectives. The backgrounds provided of research personnel does not imply a certain level of skill, and is for information purposes only.
Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.
An investor should consider a Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.
Fund Contact: Jason Myhre877-771-EVEN (3836)
View original content:http://www.prnewswire.com/news-releases/eventide-healthcare--life-sciences-fund-ranks-top-1-in-health-funds-for-the-5yr-period-300589642.html
SOURCE Eventide Asset Management
Subscribe to our Free Newsletters!
Birth Control Implant is a long-acting birth control contraceptive inserted into the arm. It is a ...
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...View All